Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

Fig. 3

Mean (SD) total plasma Aβ(1–40) and Aβ(1–42) concentrations after initial dose (weeks 1–5). Total number of patients included = 72. Each line represents mean total Aβ(1–40) or Aβ(1–42) plasma concentration following IV administration; data shown are from the phase II ABBY study (SRI cohort) for 15 mg/kg dose and phase Ib GN29632 for 30–120 mg/kg doses. Abbreviations: Aβ beta-amyloid, IV intravenous, SD standard deviation, SRI safety run-in

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193